lanabecestat: Clinical Trials

13 trials of lanabecestat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 2 withdrawn. 13 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 113Completed 11, Withdrawn 2

Follow lanabecestat: new trials by email Literature Review of lanabecestat trials Research Report on lanabecestat

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants
Lanabecestat, Iohexol - Renal Insufficiency
Phase 1WithdrawnEli Lilly and Company2018-06-012018-06-28
A Study of Lanabecestat in Healthy Female Participants Taking Oral Contraceptive
Lanabecestat, Oral Contraceptive - Healthy
Phase 1WithdrawnEli Lilly and Company2018-06-012018-06-28
A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin
Lanabecestat, Rosuvastatin - Healthy
Phase 1CompletedAstraZeneca422017-01-122019-11-01
A Study of Lanabecestat (LY3314814) in Healthy Participants
Lanabecestat - Healthy
Phase 1CompletedAstraZeneca182016-01-312019-11-01
A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants
Lanabecestat, Dabigatran etexilate - Healthy
Phase 1CompletedAstraZeneca602015-10-312019-11-01
A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants
Lanabecestat, Warfarin - Healthy
Phase 1CompletedAstraZeneca152015-09-302019-11-04
A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants
Lanabecestat, Simvastatin, Midazolam - Healthy
Phase 1CompletedAstraZeneca822015-04-302019-11-04
A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293
AZD3293 - Healthy Volunteers, Mass Balance Study
Phase 1CompletedAstraZeneca122014-05-012014-06-16
Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects
AZD3293 oral solution, AZD3293 tablet formulation A, AZD3293 tablet formulation B - Healthy Volunteers, Pharmacologic Action
Phase 1CompletedAstraZeneca12014-02-012014-04-24
AZD3293 Thorough QT Study in Healthy Male Volunteers
AZD3293, Placebo, Moxifloxacin - Alzheimer's Disease
Phase 1CompletedAstraZeneca522014-01-012014-07-03
A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers
AZD3293, Placebo - Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers
Phase 1CompletedAstraZeneca1142013-12-012016-11-04
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients
AZD3293, Placebo - Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients
Phase 1CompletedAstraZeneca472013-03-012014-04-03
A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects
AZD3293, Placebo - Healthy Young Volunteers, Healthy Elderly Volunteers
Phase 1CompletedAstraZeneca722012-12-012013-08-27

Conditions studied

Alzheimer Disease (2)  ·  Renal Insufficiency (1)

Sponsors

AstraZeneca (11)  ·  Eli Lilly and Company (2)

Countries

United States (10)  ·  Japan (1)  ·  Singapore (1)

Top investigators

Robert C Alexander, MD (3)  ·  Ronald Goldwater, MD (2)  ·  David Han, MD (1)  ·  Irene Mirkin, MD (1)  ·  Kei Sakamoto, MD, PhD (1)

Results publications

PMID 29199322